Müller, Norbert <br/><br/>
COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy.  [electronic resource] 

 -  European archives of psychiatry and clinical neuroscience  Feb 2004 
 - 14-22 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0940-1334 
<br/><br/><label>Standard No.: </label>10.1007/s00406-004-0478-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Analysis of Variance<br/>Antigens, CD--blood<br/>Antipsychotic Agents--therapeutic use<br/>Celecoxib<br/>Cyclooxygenase Inhibitors--therapeutic use<br/>Cytokines--blood<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Female<br/>Flow Cytometry--methods<br/>Humans<br/>Male<br/>Psychiatric Status Rating Scales<br/>Pyrazoles<br/>Receptors, Interleukin-2--blood<br/>Receptors, Tumor Necrosis Factor--blood<br/>Receptors, Tumor Necrosis Factor, Type I<br/>Risperidone--therapeutic use<br/>Schizophrenia--drug therapy<br/>Sulfonamides--therapeutic use<br/>T-Lymphocytes--drug effects<br/>Time Factors<br/>Treatment Outcome